CEL-SCI Corp (CVM)

0.09
0.00 1.80
AMEX : Health Care
Prev Close 0.09
Open 0.09
Day Low/High 0.09 / 0.10
52 Wk Low/High 0.36 / 0.80
Volume 5.75M
Avg Volume 3.22M
Exchange AMEX
Shares Outstanding 190.97M
Market Cap 19.10M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2016.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CEL-SCI Announces Closing Of Public Offereing And Receives Audit Opinion With Going Concern Explanation

CEL-SCI Announces Closing Of Public Offereing And Receives Audit Opinion With Going Concern Explanation

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL-SCI" or the "Company") announced today that it has received net proceeds of $3,702,760 and expects to receive the remaining $75,000 this week from its previously announced public...

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") reported financial results today for the fiscal year ended September 30, 2016.

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Corporation (NYSE MKT: CVM) reported on a communication received today from the staff of the NYSE MKT, its current listing exchange, that it considered the Company to be noncompliant with certain listing...

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has priced its public offering of common stock and warrants.

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it intends to offer and sell, subject to market and other conditions shares of its common stock and warrants to purchase common stock.

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has submitted its response to the U.

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, today announced new...

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.

CEL-SCI Reports Clinical Hold On Head And Neck Cancer Study

CEL-SCI Reports Clinical Hold On Head And Neck Cancer Study

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has received verbal notice from the U.

IIROC Trading Resumption - CVM

IIROC Trading Resumption - CVM

CEL-SCI Announces Resignation Of Its Founder For Health Reasons

CEL-SCI Announces Resignation Of Its Founder For Health Reasons

CEL-SCI Corporation (NYSE MKT:CVM) today announced that its founder, President and Chairman of the Board, Maximilian de Clara has resigned for personal health reasons, effective immediately.

CEL-SCI Reports Monthly Patient Enrollment In August For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In August For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of August it has enrolled 28 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) announced that it has closed its previously announced registered direct offering with institutional investors.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors to purchase approximately 10 million shares of its common stock and warrants exercisable for up to...

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) reported financial results for the quarter ended June 30, 2016 and updates shareholders in regards to the upcoming date for the Company's arbitration hearing against its former Clinical...

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of July it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Corporation ( NYSE MKT: CVM ) announces that it has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin).

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of June it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of May it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, announced today that it will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has closed its previously announced registered direct offering with a single healthcare dedicated institutional investor.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares of its common stock and...

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2016.

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of April it has enrolled 41 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its CEO, Geert Kersten, was recently interviewed on The RedChip Money Report television program.

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of March it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy...